|
WO2020241827A1
|
|
Chimeric antigen receptor-expressing cells targeting alk
|
|
WO2020085480A1
|
|
High-efficiency method for producing genetically modified cells
|
|
WO2020032227A1
|
|
Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
|
|
WO2019112024A1
|
|
Pyrrolidine compound
|
|
WO2019093284A1
|
|
Condensed heterocyclic compound
|
|
JP2019011379A
|
|
Silodosin-containing oral solid preparation excellent in light stability
|
|
JP2018108988A
|
|
Method for producing pyrazole derivative
|
|
WO2018117166A1
|
|
Thiazole derivative or pharmacologically acceptable salt of same
|
|
JP2018100269A
|
|
TRPM8 inhibitor
|
|
WO2018052142A1
|
|
Genetically-modified cells and method for producing same
|
|
JP2019038783A
|
|
Dry eye therapeutic agent
|
|
CN109562112A
|
|
The usage and dosage of endometriosis therapeutic agent
|
|
WO2018016547A1
|
|
Pyrrolidine derivative
|
|
JP2019011295A
|
|
Silodosin-containing oral solid preparation excellent in light stability
|
|
EP3388423A1
|
|
Nk1 receptor antagonist
|
|
JP2017014198A
|
|
Dosage regimen of therapeutic agent of ataxia in spinocerebellar ataxia
|
|
EP3686188A1
|
|
Pyrazole derivative, or pharmaceutically acceptable salt thereof
|
|
WO2016152821A1
|
|
Therapeutic agent for dry eye associated with sjogren's syndrome
|
|
JP2016094407A
|
|
Novel trpm8 inhibitor
|
|
WO2016051782A1
|
|
Oral preparation in which bitter taste of bitter-tasting drug is masked
|
